Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis

Breast

Volumn 20, Issue 5, 2011, Pages 478-480

  Mego, Michal ^a,b   Sycova Mila, Zuzana ^b   Obertova, Jana ^a,b   Rajec, Jan ^b   Liskova, Stefania ^b   Palacka, Patrik ^b   Porsok, Stefan ^b   Mardiak, Jozef ^a,b  

^a Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Breast cancer; Chemotherapy; Leptomeningeal carcinomatosis; Trastuzumab

Indexed keywords

CYTARABINE; METHOTREXATE; TRASTUZUMAB;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CARCINOMATOUS MENINGITIS; CASE REPORT; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG RESPONSE; FEMALE; HUMAN; PRIORITY JOURNAL;

EID: 80052488887     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.05.007     Document Type: Article

References (13)

1. Pestalozzi B.C., Zahrieh D., Price K.N., Holmberg S.B., Lindtner J., Collins J., et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG). Ann Oncol 2006, 17(6):935-944. International Breast Cancer Study Group (IBCSG).
2. Tsukada Y., Fouad A., Pickren J.W., Lane W.W. Central nervous system metastasis from breast carcinoma. autopsy study. Cancer 1983, 52:2349-2354.
3. Pieńkowski T., Zielinski C.C. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease. Ann Oncol 2010, 21:917-924.
4. Orlando L., Curigliano G., Colleoni M., Fazio N., Nole F., Martinelli G., et al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 2002, 22(5):3057-3059.
5. Rudnicka H., Niwińska A., Murawska M. Breast cancer leptomeningeal metastasis-the role of multimodality treatment. J Neurooncol 2007, 84:57-62.
6. Kim D.Y., Lee K.W., Yun T., Park S.R., Jung J.Y., Kim D.W., et al. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol 2003, 33:608-612.
7. Pestalozzi B.C., Brignoli S. Trastuzumab in CSF (letter). J Clin Oncol 2000, 18:2349-2351.
8. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18:23-28.
9. Perissinotti A.J., Reeves D.J. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann Pharmacother 2010, 44:1633-1640.
10. Mir O., Ropert S., Alexandre J., Lemare F., Goldwasser F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer (letter). Ann Oncol 2008, 19:1978-1980.
11. Ferrario C., Davidson A., Bouganim N., Aloyz R., Panasci L.C. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer (letter). Ann Oncol 2009, 20:792-795.
12. Oliveira M., Braga S., Passos-Coelho J.L., Fonseca R., Oliveira J. Complete response in HER2 + leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res Treat 2011, 127:841-844.
13. Pegram M.D., Konecny G.E., O'Callaghan C., Beryt M., Pietras R., Slamon D.J. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004, 96:739-749.